Cellceutix gets OK on Phase 1 cancer trial - Mass High Tech

Cellceutix gets fine on Phase 1 malignant tumor trial Mass High school Cellceutix holds the rights to eight drug compounds, including Kevetrin, which it is developing as type A treatment for certain cancers; KM-133, for the attention of psoriasis ; and KM-391, for the attention of autism. Last month, Cellceutix (OTCQB: CTIX) ... and more » Link To Article